Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

BACKGROUND: A phase 1, clinical trial to evaluate FINLAY-FR-1A vaccine in COVID-19 convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. METHODS: We studied 450 convalescent participants with a history of asymptomatic, mild, or moderate COVID-19 at the Natio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ochoa-Azze, Rolando, Chang-Monteagudo, Arturo, Climent-Ruiz, Yanet, Macías-Abraham, Consuelo, Valenzuela-Silva, Carmen, de los Ángeles García-García, María, Jerez-Barceló, Yanet, Triana-Marrero, Yenisey, Ruiz-Villegas, Laura, Dairon Rodríguez-Prieto, Luis, Guerra-Chaviano, Pedro Pablo, Sánchez-Ramírez, Belinda, Hernández-García, Tays, Orosa-Vázquez, Ivette, Díaz-Hernández, Marianniz, Chiodo, Fabrizio, Calcagno, Andrea, Ghisetti, Valeria, Rodríguez-Acosta, Mireida, Noa-Romero, Enrique, Enríquez-Puertas, Juliet, Ortega-León, Darién, Valdivia-Álvarez, Irinia, Delahanty-Fernández, Aurora, Palenzuela-Díaz, Ariel, Rodríguez-Noda, Laura, González-Mugica, Raúl, Valdés-Balbín, Yury, García-Rivera, Dagmar, Verez-Bencomo, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183216/
https://www.ncbi.nlm.nih.gov/pubmed/35691295
http://dx.doi.org/10.1016/S2213-2600(22)00100-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9183216/
https://www.ncbi.nlm.nih.gov/pubmed/35691295
http://dx.doi.org/10.1016/S2213-2600(22)00100-X

Ejemplares similares